Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 11:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 685 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Fluid Management Clear all
Completed Phase 3 Interventional Results available

Safety and Efficacy of Repeated Administrations of NurOwn® in ALS Patients

NCT03280056
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
NurOwn® (MSC-NTF cells), Placebo, Bone Marrow aspiration
Biological · Other
Lead sponsor
Brainstorm-Cell Therapeutics
Industry
Eligibility
18 Years to 60 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
6
States / cities
Irvine, California • Los Angeles, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 29, 2024 · Synced Oct 20, 2026, 11:27 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Bioequivalence of Atripla in an Oral Liquid Formulation Compared With the Tablet Formulation in Healthy Volunteers

NCT00862823
View directory record Official record
Conditions
Healthy
Interventions
tenofovir, emtricitabine and efavirenz fixed dose tablet, tenofovir, emtricitabine and efavirenz tablet added to solution
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 14, 2012 · Synced Oct 20, 2026, 11:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study in Cerebral Spinal Fluid After a Single Dose of AVI-4020

NCT00387283
View directory record Official record
Conditions
West Nile Virus
Interventions
AVI-4020 Injection
Drug
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
18 Years to 64 Years · Male only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jul 8, 2009 · Synced Oct 20, 2026, 11:27 PM EDT
Completed Not applicable Interventional Results available

Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve Decongestion Management System (DMS)

NCT05174312
View directory record Official record
Conditions
Acute Decompensated Heart Failure
Interventions
Reprieve Decongestion Management System, Diuretic
Device · Drug
Lead sponsor
Reprieve Cardiovascular, Inc
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
16
States / cities
Fairhope, Alabama • Irvine, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 20, 2026, 11:27 PM EDT
Completed Phase 4 Interventional Results available

Preventing Cardiovascular collaPse With Administration of Fluid Resuscitation Before Endotracheal Intubation

NCT03026777
View directory record Official record
Conditions
Acute Respiratory Failure, Intubation Complication
Interventions
intravenous crystalloid fluid, 500 mL
Drug
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years and older
Enrollment
337 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
7
States / cities
Birmingham, Alabama • Jefferson, Louisiana • New Orleans, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 20, 2026, 11:27 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

HPV Vaccine Reduced Dose

NCT06799494
View directory record Official record
Conditions
HPV
Interventions
Gardasil-9, Lidocaine injection, Lorazepam
Biological · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 45 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 20, 2026, 11:27 PM EDT
Completed Not applicable Interventional Results available

Effectiveness Trial for Evaluating IAHA for PFPS

NCT01811654
View directory record Official record
Conditions
Patellofemoral Pain Syndrome
Interventions
Intra-Articular Hyaluronic Acid-Euflexxa
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 40 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Oct 20, 2026, 11:27 PM EDT
Completed Phase 2 Interventional Results available

Treatment of Acute Migraine Headache in Children

NCT00355394
View directory record Official record
Conditions
Migrainous Headache
Interventions
Metoclopramide, Placebo
Drug · Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
8 Years to 18 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 30, 2015 · Synced Oct 20, 2026, 11:27 PM EDT
Active, not recruiting Phase 1 Interventional

Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma

NCT06894979
View directory record Official record
Conditions
Childhood Astrocytoma, Childhood Diffuse Intrinsic Pontine Glioma, Childhood Diffuse Midline Glioma, Childhood Glioblastoma, Childhood Malignant Glioma
Interventions
ATM Kinase Inhibitor AZD1390, Biospecimen Collection, Magnetic Resonance Imaging, Radiation Therapy, Survey Administration
Drug · Procedure · Radiation + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
12 Months to 22 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 20, 2026, 11:27 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Comprehensive Evaluation of Tobacco-Flavored vs. Non-Tobacco Flavored E-cigarettes on Smoking Behavior

NCT06260683
View directory record Official record
Conditions
Cigarette Smoking-Related Carcinoma
Interventions
Nicotine Replacement, Questionnaire Administration, Vaping
Drug · Other · Device
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
21 Years and older
Enrollment
1,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 20, 2026, 11:27 PM EDT
Completed Not applicable Interventional

Gold Factor on Knee Joint Health and Function

NCT05347602
View directory record Official record
Conditions
Knee Arthritis, Knee Osteoarthritis, Knee Pain Chronic, Knee Discomfort, Rheumatoid Arthritis, Knee Pain Swelling
Interventions
Gold Factor (Gold Nanoparticles, AuNPs), Placebo
Dietary Supplement
Lead sponsor
4Life Research, LLC
Industry
Eligibility
18 Years to 87 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 12, 2022 · Synced Oct 20, 2026, 11:27 PM EDT
Completed Not applicable Interventional

Restrictive Intravenous Fluids Trial in Sepsis

NCT03137446
View directory record Official record
Conditions
Septic Shock, Severe Sepsis
Interventions
Intravenous Fluid Cap
Other
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 31, 2018 · Synced Oct 20, 2026, 11:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Echocardiography Management for Patients Requiring Care for Non-Cardiac Surgery

NCT01050361
View directory record Official record
Conditions
Cardiovascular Risk Factors
Interventions
Transthoracic Echocardiogram (TTE)/Transesophageal Echocardiogram (TEE)
Procedure
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 100 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 29, 2023 · Synced Oct 20, 2026, 11:27 PM EDT
Completed Phase 1 Interventional

Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100

NCT01008527
View directory record Official record
Conditions
Melanoma
Interventions
CP 870,893, Peptides, Oncovir poly IC:LC
Drug · Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 24, 2015 · Synced Oct 20, 2026, 11:27 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

The Effect of Fluids on Aortic VTI During C-section

NCT04330742
View directory record Official record
Conditions
Pregnancy Related, Hemorrhage, Fluid Overload, Labor Complication
Interventions
lactated ringers
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Oct 20, 2026, 11:27 PM EDT
Recruiting Phase 3 Interventional

A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)

NCT07466316
View directory record Official record
Conditions
Rhabdomyosarcoma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Computed Tomography, Cyclophosphamide, Dactinomycin, Irinotecan Hydrochloride, Lumbar Puncture, Lymph Node Biopsy, Magnetic Resonance Imaging, Positron Emission Tomography, Radiation Therapy, Resection, Survey Administration, Vincristine Sulfate, Vinorelbine Tartrate
Procedure · Drug · Biological + 2 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 50 Years
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
86
States / cities
Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 71 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 20, 2026, 11:27 PM EDT
Completed No phase listed Observational

ZYNEX Cardiac Monitor in Patients Having Noncardiac Surgery

NCT05536258
View directory record Official record
Conditions
Noncardiac Surgery
Interventions
Fluid
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
21 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Oct 20, 2026, 11:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study of a Single Dose of AVI-4126 (RESTEN-NG®) in Cerebral Spinal Fluid

NCT00343148
View directory record Official record
Conditions
Neoplasms
Interventions
AVI-4126 Injection (RESTEN-NG®)
Drug
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
18 Years to 64 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jul 8, 2009 · Synced Oct 20, 2026, 11:27 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Ad4-HIV Envelope Vaccine Vectors in Healthy Volunteers

NCT03878121
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Ad4-Env145NFL, Ad4-Env150KN, VRC-HIVRGP096-00-VP (Trimer 4571) with alum
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 20, 2026, 11:27 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older

NCT04904549
View directory record Official record
Conditions
COVID-19
Interventions
SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent D614) (primary series), SARS-CoV-2 adjuvanted recombinant protein vaccine (bivalent D614 + B.1.351) (primary series), Placebo, SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent B.1.351) (booster dose) >= 4 months after last vaccination, SARS-CoV-2 adjuvanted recombinant protein vaccine(monovalent D614)(primary series)& SARS-CoV-2 adjuvanted recombinant protein vaccine(monovalent B.1.351)(booster dose)>=4 months after last vaccination
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
23,670 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
23
States / cities
Birmingham, Alabama • Huntsville, Alabama • Rolling Hills Estates, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 20, 2026, 11:27 PM EDT
Completed No phase listed Observational

Antibiotic Concentration After Delivery to Middle Ear for Chronic Suppurative Otitis Media

NCT05133258
View directory record Official record
Conditions
Chronic Suppurative Otitis Media
Interventions
Aspiration of middle ear fluid following standard-of-care delivery of ciprofloxacin and dexamethasone suspension
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 20, 2026, 11:27 PM EDT
Completed Phase 2 Interventional Results available

A Study of Flurpiridaz (18F) Injection for PET Imaging for Assessment of MPI Quality Using HPLC and SPE Manufacturing Processes

NCT04594941
View directory record Official record
Conditions
Coronary Artery Disease (CAD), Ischemic Heart Disease
Interventions
Flurpiridaz (18F) Injection
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
5
States / cities
Hialeah, Florida • Miami, Florida • North Miami Beach, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 20, 2026, 11:27 PM EDT
Not listed Phase 1 Interventional

Ovarian Rejuvenation Using Platelet Rich Plasma (PRP) & Autologous Tissue Stromal Vascular Fraction (tSVF) and Cell Enriched tSVF

NCT04444245
View directory record Official record
Conditions
Ovarian Failure, Perimenopausal Disorder, Hormone Disturbance
Interventions
lipoaspiration harvest tSVF, Platelet Rich Plasma, Endovaginal Ultrasound, Cellular Isolation cSVF, Normal Saline (NS) .9% 10 mL Injection, emulsification tSVF
Procedure · Device · Drug
Lead sponsor
Black Tie Medical, Inc.
Industry
Eligibility
35 Years to 60 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Colchester, Vermont
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced Oct 20, 2026, 11:27 PM EDT
Completed No phase listed Observational

Predicting Volume Response Study

NCT01656954
View directory record Official record
Conditions
Shock, Hypovolemia
Interventions
Passive Leg Raise (PLR)
Procedure
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 17, 2016 · Synced Oct 20, 2026, 11:27 PM EDT